Question:

What is meant by generic drugs? Explain its importance in the light of judicial decisions in India.

Updated On: Jul 13, 2026
Show Solution
collegedunia
Verified By Collegedunia

Approach Solution - 1

Generic drugs in India are medicines that are identical in chemical composition and effectiveness to brand-name drugs. They are sold under their chemical names, not brand names, and are often cheaper. This helps more people afford necessary medications.

Laws like the Drugs and Cosmetics Act of 1940 regulate how generic drugs are made, sold, and distributed in India. These laws have been updated to encourage more production and use of generic drugs, which are crucial for making healthcare more affordable and accessible to everyone.

Court decisions have also shaped how generic drugs are used in India. For example, in the Novartis case of 2013, the Supreme Court ruled that certain drugs couldn't be patented under Indian law if they weren't new or innovative enough. This decision supported the availability of cheaper generic versions of essential medicines.

Another important case involved the drug Nexavar in 2014, where the court allowed a generic version to be made by Natco Pharma at a lower cost. This highlighted how Indian law allows for compulsory licensing of drugs to ensure public access to affordable medications when needed.

India's approach to promoting generic drugs isn't just about local impact—it aligns with global efforts to make healthcare more affordable worldwide. By encouraging competition among drug manufacturers, prices are driven down, and more treatment options become available, especially for chronic illnesses.

Despite these benefits, challenges remain. Ensuring the quality and safety of generic drugs is crucial. Regulatory bodies like the CDSCO monitor this closely through strict approval processes and ongoing checks after drugs are on the market.

In summary, generic drugs have transformed India's healthcare by making essential medicines cheaper and more widely available. Court decisions have played a key role in supporting this, emphasizing public health needs over purely commercial interests. Moving forward, it's important to continue improving regulations and addressing challenges to ensure everyone has access to the medicines they need.

Was this answer helpful?
0
0
Show Solution
collegedunia
Verified By Collegedunia

Approach Solution -2

This question has two parts: what a generic drug is, and why courts have protected the space for generic drugs to exist. The second part is really about patent law, since a generic drug can only be sold once a patent barrier is gone or is denied in the first place.

What makes a drug "generic":
A generic drug has the same active ingredient, strength, dosage form, and intended effect as a brand-name drug already approved for sale, but it is sold under its chemical or International Non-proprietary Name rather than a trademarked brand. Because the original manufacturer has already proven the drug safe and effective, a generic maker only needs to show bioequivalence, that it behaves the same way in the body, not repeat the original clinical trials from scratch. That is what keeps generic drugs far cheaper.

The patent law provision that decides whether a generic can exist:
Section 3(d) of the Patents Act, 1970, blocks a patent on a new form of an already known substance unless the applicant shows it works meaningfully better, not just differently, than the known substance. This section exists specifically to stop "evergreening," where a company makes a trivial tweak to an existing drug just before its patent expires to extend its monopoly and delay generics.

Novartis AG v. Union of India (2013):
Novartis sought a patent for a particular crystalline form of imatinib, sold as Glivec, a leukemia drug. The Supreme Court refused the patent under Section 3(d), holding that Novartis had not shown the new form was significantly more effective than the already-known compound. This kept the door open for Indian companies to keep selling generic imatinib at a fraction of the branded price, and became the leading case for reading Section 3(d) strictly in favour of access to medicine.

Natco Pharma v. Bayer Corporation (2012), the compulsory licence route:
Even where a patent is validly granted, Section 84 of the Patents Act lets a generic company apply for a compulsory licence if the patented drug is not reasonably affordable or available to the public. This was used for the first time in India for Nexavar, a kidney and liver cancer drug patented by Bayer. The Controller General of Patents granted Natco Pharma a licence to manufacture and sell a generic version at a much lower price, a decision the Bombay High Court and the Intellectual Property Appellate Board upheld, reading it consistently with the flexibilities the Doha Declaration on TRIPS and Public Health recognises for public health emergencies.

Evaluation:
Between them, Section 3(d) and Section 84 give India two separate tools, one to stop weak patents from being granted at all, the other to override a strong patent when the price is genuinely out of reach for patients. Government schemes like Jan Aushadhi build on the same logic by selling generics directly at government-run stores. The tension that remains is international: pharmaceutical companies and some trading partners have criticised India's use of both provisions as weakening patent protection, so the balance between rewarding innovation and keeping medicine affordable is argued over as much in trade negotiations as in court.

Was this answer helpful?
0
0

Top CLAT PG Legal Studies Questions

View More Questions

Top CLAT PG Public International Law Questions

View More Questions

Top CLAT PG Questions

View More Questions